The research is being done to test whether the active study drug, sotagliflozin, is safe in patients who have diabetes, kidney disease and who are at risk for cardiovascular events such as heart attack and stroke.
Anticipated date that enrolment will close: June 2019
We are seeking volunteers for the SURPASS-4 study which is a clinical trial investigating the safety and effectiveness of tirzepatide when taken once weekly compared to insulin taken once daily in people with type 2 diabetes and increased cardiovascular risk.
We are seeking people with a condition, Diabetic Kidney Disease (DKD), to participate in a study. The study is testing a new way of treating DKD with an drug called "propagermanium".